Company Analysis
Sign in

Kodiak Sciences Inc (KOD)

Nasdaq: KOD · Biological Products, (No Diagnostic Substances) · Palo Alto, CA · filing with the SEC since 2009
Full chart Alerts Compare
Grade6.0
◀ Past 6.2● Present 6.3▶ Future 5.8
6 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

15 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Kodiak Sciences Inc’s names, not what it holds today.

Patents granted
15
15 utility, 1976 to Dec 31, 2025
Granted in 2025
2
Against 2 in 2024 and 3 in 2023
Applications published
37
1 of them in 2025
Names they are printed under
3
its own name, a former name
By yearGrantedApplications published
'10'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals8
Biotechnology2
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name3 counted
KODIAK SCIENCES INC. its own name
named as the applicant on its applications, in US
0 granted
27 published
KODIAK SCIENCES INC. its own name
US, as the owner printed on each patent
13 granted
2 published
OLIGASIS, LLC a former name
US, as the owner printed on each patent
2 granted
8 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Nov 11, 202512,466,879Complement factor D antagonist antibodies and conjugates thereofPharmaceuticalsKODIAK SCIENCES INC.
Feb 4, 202512,214,044Factor VIII zwitterionic polymer conjugatesPharmaceuticalsKODIAK SCIENCES INC.
Aug 27, 202412,071,476IL-6 antibodies and fusion constructs and conjugates thereofPharmaceuticalsKODIAK SCIENCES INC.
Feb 27, 202411,912,784Methods of treating an eye disorderPharmaceuticalsKODIAK SCIENCES INC.
Nov 21, 202311,819,531Multifunctional zwitterionic polymer conjugatesPharmaceuticalsKODIAK SCIENCES INC.
Feb 28, 202311,590,235Factor VIII zwitterionic polymer conjugatesPharmaceuticalsKODIAK SCIENCES INC.
Feb 21, 202311,584,790Complement factor D antagonist antibodies and conjugates thereofPharmaceuticalsKODIAK SCIENCES INC.
Oct 26, 202111,155,610Dual PDGF/VEGF antagonistsBiotechnologyKODIAK SCIENCES INC.
Jul 27, 202111,071,771Butyrylcholinesterase zwitterionic polymer conjugatesBiotechnologyKODIAK SCIENCES INC.
Jul 20, 202111,066,465Antibodies and conjugates thereofPharmaceuticalsKODIAK SCIENCES INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 25, 20252025/0388568NLRP3 INHIBITORSOrganic fine chemistryKODIAK SCIENCES INC.
Nov 7, 20242024/0368267IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOFPharmaceuticalsKODIAK SCIENCES INC.
Sep 5, 20242024/0293585HIGH MOLECULAR WEIGHT ZWITTERION-CONTAINING POLYMERSMacromolecular chemistry, polymersKODIAK SCIENCES INC.
Jul 18, 20242024/0238427METHODS OF TREATING AN EYE DISORDERPharmaceuticalsKODIAK SCIENCES INC.
Jun 27, 20242024/0209076USE OF IL-6 ANTIBODIES AND VEGF TRAPS, AND FUSION CONSTRUCTS AND CONJUGATES THEREOFPharmaceuticalsKODIAK SCIENCES INC.
Jun 20, 20242024/0197810MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATESPharmaceuticalsKODIAK SCIENCES INC.
Mar 14, 20242024/0084043METHODS OF TREATING AN EYE DISORDERPharmaceuticalsKODIAK SCIENCES INC.
Nov 30, 20232023/0382983COMPLEMENT FACTOR D ANTAGONIST ANTIBODIES AND CONJUGATES THEREOFPharmaceuticalsKODIAK SCIENCES INC. · patent 12,466,879 granted from it
Sep 7, 20232023/0277616MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATESPharmaceuticalsKODIAK SCIENCES INC. · patent 11,819,531 granted from it
Aug 10, 20232023/0250133METHODS OF PURIFYING A PRODUCTBiotechnologyKODIAK SCIENCES INC.
What it applied for, 2024 to 2025: Pharmaceuticals 5 · Macromolecular chemistry, polymers 1 · Organic fine chemistry 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton KOD · research, not advice